Barbara Nelsen, Ph.D., M.B.A.

Barbara Nelsen, Ph.D., M.B.A.

Boston, Massachusetts, United States
1K followers 500 connections

Join to view profile

About

Life Science Executive recognized as a results-oriented strategic thinker, persuasive…

Articles by Barbara

See all articles

Activity

Experience

  • Nelsen Biomedical Graphic

    Nelsen Biomedical

  • -

    Minneapolis, Minnesota, United States

  • -

    Greater Minneapolis-St. Paul Area

  • -

  • -

    Minneapolis, Boston and San Francisco

  • -

  • -

Publications

  • The State of Alzheimer's Disease: Focus and Funding

    https://www.nelsenbiomedical.com/market-reports/

    This past year we at Nelsen Biomedical completed a large landscape analysis of Alzheimer’s disease. We interviewed leaders in industry, the investment community, foundations and non-profits in addition to clinicians and scientists. We identified key barriers to progress and novel scientific and clinical areas for focus and funding.

    With the 2019 Q1 failures of Roche and Biogen/Eisai’s Phase III trials, it is time to share some key points on where the field is headed and what this means…

    This past year we at Nelsen Biomedical completed a large landscape analysis of Alzheimer’s disease. We interviewed leaders in industry, the investment community, foundations and non-profits in addition to clinicians and scientists. We identified key barriers to progress and novel scientific and clinical areas for focus and funding.

    With the 2019 Q1 failures of Roche and Biogen/Eisai’s Phase III trials, it is time to share some key points on where the field is headed and what this means for both patients and the industry.

  • Progress in the Treatment of Muscular Dystrophies

    https://www.nelsenbiomedical.com/market-reports/

    With a small patient population and a challenging breadth of disease types and underlying biological and genetic causes, the dystrophies have historically lacked attention from the biopharma industry as a value-driver for new drug development. New technical capabilities in gene therapy & gene editing and seed funds from philanthropic organizations focused on de-risking early stage drug development have changed the playing field.

    In this report, we provide an overview of the current state…

    With a small patient population and a challenging breadth of disease types and underlying biological and genetic causes, the dystrophies have historically lacked attention from the biopharma industry as a value-driver for new drug development. New technical capabilities in gene therapy & gene editing and seed funds from philanthropic organizations focused on de-risking early stage drug development have changed the playing field.

    In this report, we provide an overview of the current state of funding, therapeutics in development, and novel technical approaches towards treating this group of challenging diseases.

  • Manufacturing Matters in Cell Therapy

    Nelsen Biomedical

    The focus of this report is to outline recent key advances in the manufacturing of cellular therapies and to clearly outline the state of the cell therapy market. Here we delineate the manufacturing process in detail, including key factors that influence companies to manufacture in-house or to outsource, elements essential to the success of current leaders in the cell production field, and competitive intelligence on large and small scale automated cell culture equipment. Recent market trends…

    The focus of this report is to outline recent key advances in the manufacturing of cellular therapies and to clearly outline the state of the cell therapy market. Here we delineate the manufacturing process in detail, including key factors that influence companies to manufacture in-house or to outsource, elements essential to the success of current leaders in the cell production field, and competitive intelligence on large and small scale automated cell culture equipment. Recent market trends are analyzed for a clear view of the cell therapy industry landscape, revealing near term opportunities for growth in manufacturing as well as market entrance and adoption strategies for providers and services for cell manufacturing.

  • The View Beyond Venture Capital

    Nature Biotechnology

    A primer for entrepreneurs on alternative funding options, the many options beyond venture capital. How to identify, prioritize, and connect with these potential investors and alternative sources of capital.

    See publication

  • Platform Technologies in Regenerative Medicine: Maximizing the Technology Early in the Process

    World Stem Cell Summit

  • Commercialization of the DECELL/RECELL Technology Platform

    World Stem Cell Summit

    Other authors

  • Anticipating a Future for Biopharma Industries in Minnesota: Pursuing the Niche

    Destination 2025: BBAM

    Other authors

  • How to Translate Technology: From Bench to Bedside at the University of MInnesota

    Journal of Cardiovascular Translational Research

Organizations

  • New York Academy of Sciences

    member

    - Present

  • ISSCR

    -

  • Life Science Alley

    -

Recommendations received

6 people have recommended Barbara

Join now to view

View Barbara’s full profile

  • See who you know in common
  • Get introduced
  • Contact Barbara directly
Join to view full profile

Other similar profiles

Explore more posts

Explore collaborative articles

We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.

Explore More

Add new skills with these courses

See all courses